血液透析患者丙型肝炎病毒医院感染的危险因素分析

目的:分析进行血液透析的患者感染丙型肝炎病毒的可能危险因素.方法:将2016年3月至2018年2月收治的,在我院进行血液透析的78例患者作为研究对象.根据是否感染丙型肝炎病毒,将入组的患者分为感染组(n=23)和未感染组(n=55).详细记录患者的相关临床资料.对感染组和未感染组患者的资料进行单因素分 析,并对有可能存...     

适应性免疫在丙型肝炎病毒持续感染中的作用

丙型肝炎病毒(hepatitis C virus,HCV)是一种黄病毒属的单股正链嗜肝RNA病毒,是引起慢性肝病的主要病原体.机体在抗HCV感染免疫过程中,固有免疫(innate immunity)与适应性免疫(adaptive immunity)相互依赖,互相协作.     

丙型肝炎病毒在人T淋巴细胞中的体外感染

用丙型肝炎病毒（ＨＣＶ）ＲＮＡ阳性的血清感染人类Ｔ淋巴细胞（Ｍｏｌｔ－４），１２小时后继续孵化１～２８天，将感染后的产物用聚合酶链反应（ＰＣＲ）测定，于第１、２、３天和第８天发现ＨＣＶ－ＲＮＡ的正链，第２和第８天发现ＨＣＶ－ＲＮＡ的负链。     

丙型肝炎病毒主要流行亚型包膜糖蛋白变异性分析

目的分析不同亚型丙型肝炎病毒（HCV）包膜糖蛋白E1和E2的变异性。方法从HCV基因数据库中获得不同亚型HCV包膜序列,并利用生物信息学方法进行核苷酸序列变异性、包膜糖蛋白亲水性性及糖基化位点分析。结果与其他亚型相比,1b亚型HCV包膜糖蛋白E1和E2区核苷酸的变异性最高,且E1区的变异性高于E2区;在E1区55,72位和102—112位氨基酸处1b亚型亲水性较大;1b亚型的包膜糖蛋白E1区N一糖基化位点数最多,且在60位氨基酸处单独有一糖基化位点。结论与E2区相比,E1区的高突变可能与1b型HCV致病性较强关系密切,且1b亚型E1蛋白的大量糖基化也可能存病毒的致病及角癌挑浼中有一审作用。     

吉林省延吉市丙型肝炎病毒的流行调查

吉林省延吉市丙型肝炎病毒的流行调查李英信任东鲜李英珠李玉雨ＨｉｄｅｋｉＡｉｚａｋｉＴａｔｕｏＭｉｙａｍｕｒａ我们对吉林省延吉市的５６０份献血员和５２０份建康人血清用酶联免疫吸附试验（ＥＬＩＳＡ）进行抗－ＨＣＶ抗体的检测，试剂为国产ＨＣＶｃ３３、ＣＰ１...     

乙型慢性肝炎重叠感染丙型和丁型肝炎病毒的临床分析

乙型慢性肝炎重叠感染丙型和丁型肝炎病毒的临床分析姚桢，刘茂才，王朝栋报道２６７例乙型慢性肝炎（含慢迁肝１８７例，慢活肝８０例）的丙型肝炎病毒（ＨＣＶ）和丁型肝炎病毒（ＨＤＶ）重叠感染情况并作临床简要分析。调查患者血清ＨＢｓＡｇ、抗－ＨＢｓ、ＨＢｅＡｇ...     

庚型肝炎病毒与乙型,丙型肝炎病毒重叠感染的临床分析

庚型肝炎病毒与乙型、丙型肝炎病毒重叠感染的临床分析赵和平赵素莲张玲荣郎丽娟庚型肝炎病毒（ＨＧＶ）主要经血传播，可致急、慢性肝炎和无症状携带状态〔１〕。我们采用抗－ＨＧＶ酶联免疫试验（ＥＩＡ）筛选阳性血清，再用逆转录套式聚合酶链反应法（ＲＴ－ｎＰＣＲ）...     

乙型和丙型肝炎病毒双重感染病人的细胞免疫应答：丙型肝炎病毒起主要作用

乙型和丙型肝炎病毒双重感染病人的细胞免疫应答：丙型肝炎病毒起主要作用〔英〕／ＴｓａｉＳＬ…Ｈｅｐａｔｏｌｏｇｙ。－１９９５，２１（４）．－９０８～９１２乙型肝炎病毒（ＨＢＶ）和丙型肝炎病毒（ＨＣＶ）感染所致的肝细胞损害与免疫机理有关，近期关于ＨＢＶ及...     

新疆地区丙型肝炎病毒与庚型肝炎病毒重叠感染的检测

１９９６年ＪｅｆＬｉｎｎｅｎ等报道了庚型肝炎病毒（ＨＧＶ）全序列，并认其是一种新的人类肝炎病毒，其主要经血液传播，可引起急、慢性及重型肝炎，可与丙型肝炎病毒（ＨＣＶ）、乙型肝炎病毒ＨＢＶ重叠感染，呈全球分布。中国新疆是一个多民族地区，为了解新疆不同地...     

性滥妇女乙型肝炎病毒和丙型肝炎病毒的感染

性滥妇女乙型肝炎病毒和丙型肝炎病毒的感染姚家珮，朱传琳，葛安平，张绍刚，张文瑾，白文林，许健（中国人民解放军３０２医院，北京１０００３９）肝炎病毒可以存在于血液、唾液、精液、尿液等体液中，故亦能通过性行为传给对方。当前性传播疾病在我国有日益增长的趋势...     

澳门地区丙型肝炎病毒基因型分析

应用逆转录－ＤＮＡ聚合酶链反应及ＤＮＡ序列分析，对采自澳门地区４３例抗－丙型肝炎病毒抗体阳性的慢性肝火患者及５５例血液透析患者血清进行了ＨＣＶ ＲＮＡ检测及基因型分析。     

丙型肝炎病毒混合基因亚型感染的研究进展

丙型肝炎病毒（Hepatitis Cvirus,HCV）感染的慢性化程度高,极易发展成肝硬化和肝癌,已成为威胁人类健康的重要病原体之一。HCV具有很高的变异性,依其基因组的差异性大小可分为基因型（31％-33％）、亚型（20％～25％）和准种（≤3％）。     

基因芯片在丙型肝炎病毒分型检测中的评价

为研究HCV基因分型芯片检测丙型肝炎患者的基因型,以测序法进行对比,并探讨了IFN治疗慢性丙肝疗效与基因型的关系。采用基因芯片的方法对20例慢性丙型肝炎患者进行分型,并通过测序验证。结果基因芯片和测序结果完全一致。20例丙肝患者中18例为1b,2例为2a,并且IFN治疗效果2a较1b型为优。HCV分型芯片检测HCV分型,特异性强、灵敏度高、结果准确,支持HCVRNA基因型在评价IFN疗效中十分重要的观点。     

丙型肝炎病毒在肝细胞癌发生中的作用

HCV与肝细胞癌发生关系密切。HCV是典型的RNA病毒，它不整合到宿主基因组中，其致癌机理为目前研究热点之一。本文就近年来HCV致癌机理研究方面的成果进行了综述。     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.